To further define the relative impact of inhibiting one-carbon metabolism on these cytosolic pathways in Ewing sarcoma cells, we first tested whether providing exogenous metabolites can rescue cells from the growth suppression caused by pharmacologic inhibition of SHMT1 and SHMT2. The gene discussed is SHMT2; the disease is Ewing sarcoma.